These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33942532)

  • 1. Nanoparticle-based applications for cervical cancer treatment in drug delivery, gene editing, and therapeutic cancer vaccines.
    Zhou P; Liu W; Cheng Y; Qian D
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1718. PubMed ID: 33942532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy.
    Aghamiri S; Talaei S; Roshanzamiri S; Zandsalimi F; Fazeli E; Aliyu M; Kheiry Avarvand O; Ebrahimi Z; Keshavarz-Fathi M; Ghanbarian H
    Expert Opin Drug Deliv; 2020 Jun; 17(6):753-766. PubMed ID: 32281426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
    Chen F; Alphonse M; Liu Q
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy.
    Wang W; Hao Y; Liu Y; Li R; Huang DB; Pan YY
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jan; 13(1):e1654. PubMed ID: 32700465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
    Verma R; Sahu R; Singh DD; Egbo TE
    Semin Cell Dev Biol; 2019 Dec; 96():44-52. PubMed ID: 30986568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats/Cas9 Delivered by pH-Sensitive Cationic Liposomes.
    Zhen S; Liu Y; Lu J; Tuo X; Yang X; Chen H; Chen W; Li X
    Hum Gene Ther; 2020 Mar; 31(5-6):309-324. PubMed ID: 31973584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advancement of nanomedicine-based targeted delivery for cervical cancer treatment.
    Yadav R; Das PP; Sharma S; Sengupta S; Kumar D; Sagar R
    Med Oncol; 2023 Nov; 40(12):347. PubMed ID: 37930458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highlights in nanocarriers for the treatment against cervical cancer.
    Medina-Alarcón KP; Voltan AR; Fonseca-Santos B; Moro IJ; de Oliveira Souza F; Chorilli M; Soares CP; Dos Santos AG; Mendes-Giannini MJS; Fusco-Almeida AM
    Mater Sci Eng C Mater Biol Appl; 2017 Nov; 80():748-759. PubMed ID: 28866224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
    Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
    J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Delivery of CRISPR/Cas9 Targeting HPV Oncogenes Is Effective at Eliminating Established Tumors.
    Jubair L; Fallaha S; McMillan NAJ
    Mol Ther; 2019 Dec; 27(12):2091-2099. PubMed ID: 31537455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle-based drug delivery to the vagina: a review.
    Ensign LM; Cone R; Hanes J
    J Control Release; 2014 Sep; 190():500-14. PubMed ID: 24830303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel.
    Guo P; Yang J; Huang J; Auguste DT; Moses MA
    Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18295-18303. PubMed ID: 31451668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosome/Liposome-like Nanoparticles: New Carriers for CRISPR Genome Editing in Plants.
    Alghuthaymi MA; Ahmad A; Khan Z; Khan SH; Ahmed FK; Faiz S; Nepovimova E; Kuča K; Abd-Elsalam KA
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response.
    Rawding PA; Bu J; Wang J; Kim DW; Drelich AJ; Kim Y; Hong S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Mar; 14(2):e1752. PubMed ID: 34414690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
    Eskander RN; Tewari KS
    Clin Ther; 2015 Jan; 37(1):20-38. PubMed ID: 25592089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanocellulose-based Delivery Systems and Cervical Cancer: Review of the Literature.
    Sadoughi F; Hallajzadeh J; Asemi Z; Mansournia MA; Yousefi B
    Curr Pharm Des; 2021; 27(46):4707-4715. PubMed ID: 34579625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing.
    Duan L; Ouyang K; Xu X; Xu L; Wen C; Zhou X; Qin Z; Xu Z; Sun W; Liang Y
    Front Genet; 2021; 12():673286. PubMed ID: 34054927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies.
    Vici P; Pizzuti L; Mariani L; Zampa G; Santini D; Di Lauro L; Gamucci T; Natoli C; Marchetti P; Barba M; Maugeri-Saccà M; Sergi D; Tomao F; Vizza E; Di Filippo S; Paolini F; Curzio G; Corrado G; Michelotti A; Sanguineti G; Giordano A; De Maria R; Venuti A
    Expert Rev Vaccines; 2016 Oct; 15(10):1327-36. PubMed ID: 27063030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.